Small,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 15, 2024
Abstract
The
treatment
of
brain
diseases
has
always
been
the
focus
attention.
Due
to
presence
blood‐brain
barrier
(BBB),
most
small
molecule
drugs
are
difficult
reach
brain,
leading
undesirable
therapeutic
outcomes.
Recently,
nanomedicines
that
can
cross
BBB
and
precisely
target
lesion
sites
have
emerged
as
thrilling
tools
enhance
early
diagnosis
treat
various
intractable
disorders.
Extensive
research
shown
reactive
oxygen
species
(ROS)
play
a
crucial
role
in
occurrence
progression
diseases,
including
tumors
neurodegenerative
(NDDs)
such
Alzheimer's
disease,
Parkinson's
stroke,
or
traumatic
injury,
making
ROS
potential
target.
In
this
review,
on
structure
function
well
mechanisms
first
elaborated
through
which
nanomedicine
traverses
it.
Then,
recent
studies
production
summarized
photodynamic
therapy
(PDT),
chemodynamic
(CDT),
sonodynamic
(SDT)
for
treating
tumors,
depletion
NDDs.
This
provides
valuable
guidance
future
design
ROS‐targeted
disease
treatment.
ongoing
challenges
perspectives
developing
nanomedicine‐based
management
also
discussed
outlined.
Frontiers in Medicine,
Journal Year:
2024,
Volume and Issue:
11
Published: July 22, 2024
This
research
is
an
analysis
of
multiple
regression
models
developed
for
predicting
ketoprofen
solubility
in
supercritical
carbon
dioxide
under
different
levels
T(K)
and
P(bar)
as
input
features.
Solubility
the
drug
was
correlated
to
pressure
temperature
major
operational
variables.
Selected
this
study
are
Piecewise
Polynomial
Regression
(PPR),
Kernel
Ridge
(KRR),
Tweedie
(TDR).
In
order
improve
performance
models,
hyperparameter
tuning
executed
utilizing
Water
Cycle
Algorithm
(WCA).
Among,
PPR
model
obtained
best
performance,
with
R
2
score
0.97111,
alongside
MSE
1.6867E-09
MAE
3.01040E-05.
Following
closely,
KRR
demonstrated
a
good
0.95044,
2.5499E-09,
3.49707E-05.
contrast,
TDR
produces
lower
0.84413
together
7.4249E-09
5.69159E-05.
RSC Advances,
Journal Year:
2024,
Volume and Issue:
14(48), P. 35568 - 35577
Published: Jan. 1, 2024
Over
the
last
few
decades,
nanotechnology
has
established
to
be
a
promising
field
in
medicine.
A
remaining
dominant
challenge
today's
pharmacotherapy
is
limited
selectivity
of
active
pharmaceutical
ingredients
and
associated
undesirable
side
effects.
Controlled
drug
release
can
promoted
by
smart
delivery
systems,
which
embedded
API
primarily
depending
on
specific
stimuli.
Consequently,
also
microenvironment
tumor
tissue
used
advantageously.
Dithiothreitol
(DTT)
based
self-immolative
polydisulfides
were
synthesized
that
preferentially
respond
pathologically
increased
glutathione
(GSH)
concentrations,
as
found
solid
tumors.
The
synthesis
with
different
degrees
polymerisation
was
investigated
well
copolymer
consisting
dithiothreitol
butanedithiol
(BDT).
Toxicity
tests
carried
out
pure
polymers
their
degradation
products.
ability
degrade
examined
at
pathological
physiological
concentrations
order
test
suitability
polymer
matrix
for
nanoparticulate
carrier
systems.
In
addition,
processability
one
into
nanoparticles
behaviour
glutathione.
Small,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 15, 2024
Abstract
The
treatment
of
brain
diseases
has
always
been
the
focus
attention.
Due
to
presence
blood‐brain
barrier
(BBB),
most
small
molecule
drugs
are
difficult
reach
brain,
leading
undesirable
therapeutic
outcomes.
Recently,
nanomedicines
that
can
cross
BBB
and
precisely
target
lesion
sites
have
emerged
as
thrilling
tools
enhance
early
diagnosis
treat
various
intractable
disorders.
Extensive
research
shown
reactive
oxygen
species
(ROS)
play
a
crucial
role
in
occurrence
progression
diseases,
including
tumors
neurodegenerative
(NDDs)
such
Alzheimer's
disease,
Parkinson's
stroke,
or
traumatic
injury,
making
ROS
potential
target.
In
this
review,
on
structure
function
well
mechanisms
first
elaborated
through
which
nanomedicine
traverses
it.
Then,
recent
studies
production
summarized
photodynamic
therapy
(PDT),
chemodynamic
(CDT),
sonodynamic
(SDT)
for
treating
tumors,
depletion
NDDs.
This
provides
valuable
guidance
future
design
ROS‐targeted
disease
treatment.
ongoing
challenges
perspectives
developing
nanomedicine‐based
management
also
discussed
outlined.
